Cardinal Health releases new report on the cell and gene therapy industry
Cardinal Health (NYSE: CAH) has released its 2025 Advanced Therapies Report, providing comprehensive insights into the cell and gene therapy (CGT) industry. The report, based on a survey of over 100 healthcare providers, reveals that the advanced therapy industry is projected to have over 200 therapies approved and treat more than 100,000 U.S. patients by 2030.
Key findings highlight significant challenges in CGT adoption, with 56% of respondents citing financial constraints and 54% pointing to inadequate reimbursement as major barriers. The report emphasizes the need for improved collaboration across industry stakeholders, with 69% of respondents supporting strategic initiatives between payers and manufacturers. Additionally, 64% identified insufficient social support as the primary reason patients don't receive needed CGT treatments.
Cardinal Health (NYSE: CAH) ha pubblicato il suo Rapporto sulle Terapie Avanzate 2025, offrendo un'analisi approfondita del settore delle terapie cellulari e geniche (CGT). Il rapporto, basato su un sondaggio condotto su oltre 100 operatori sanitari, rivela che si prevede che l'industria delle terapie avanzate avrà più di 200 terapie approvate e tratterà oltre 100.000 pazienti negli Stati Uniti entro il 2030.
I risultati principali evidenziano sfide significative nell'adozione delle CGT, con il 56% degli intervistati che indica vincoli finanziari e il 54% che segnala un rimborso insufficiente come ostacoli principali. Il rapporto sottolinea la necessità di una collaborazione migliorata tra i vari attori del settore, con il 69% degli intervistati che supporta iniziative strategiche tra pagatori e produttori. Inoltre, il 64% ha individuato un supporto sociale insufficiente come la principale ragione per cui i pazienti non ricevono i trattamenti CGT necessari.
Cardinal Health (NYSE: CAH) ha publicado su Informe de Terapias Avanzadas 2025, ofreciendo una visión completa de la industria de terapias celulares y génicas (CGT). El informe, basado en una encuesta a más de 100 proveedores de atención médica, revela que se proyecta que la industria de terapias avanzadas tendrá más de 200 terapias aprobadas y tratará a más de 100,000 pacientes en EE. UU. para 2030.
Los hallazgos clave destacan desafíos significativos en la adopción de CGT, con un 56% de los encuestados citando limitaciones financieras y un 54% señalando un reembolso insuficiente como principales barreras. El informe enfatiza la necesidad de una mejor colaboración entre los actores de la industria, con un 69% de los encuestados apoyando iniciativas estratégicas entre pagadores y fabricantes. Además, un 64% identificó el apoyo social insuficiente como la razón principal por la que los pacientes no reciben los tratamientos CGT necesarios.
Cardinal Health (NYSE: CAH)는 2025년 첨단 치료 보고서를 발표하며 세포 및 유전자 치료(CGT) 산업에 대한 포괄적인 통찰을 제공했습니다. 100명 이상의 의료 제공자를 대상으로 한 설문조사를 기반으로 한 이 보고서는 첨단 치료 산업이 2030년까지 200개 이상의 치료법이 승인되고 10만 명 이상의 미국 환자를 치료할 것으로 예상된다고 밝혔습니다.
주요 결과는 CGT 도입에 있어 상당한 어려움을 강조하며, 응답자의 56%가 재정적 제약을, 54%가 불충분한 보험 보상을 주요 장애물로 꼽았습니다. 보고서는 업계 이해관계자 간 협력 강화의 필요성을 강조하며, 응답자의 69%가 지불자와 제조업체 간 전략적 이니셔티브를 지지한다고 밝혔습니다. 또한, 64%가 환자들이 필요한 CGT 치료를 받지 못하는 주된 이유로 사회적 지원 부족을 지적했습니다.
Cardinal Health (NYSE : CAH) a publié son Rapport sur les Thérapies Avancées 2025, offrant des informations complètes sur l'industrie des thérapies cellulaires et géniques (CGT). Le rapport, basé sur une enquête auprès de plus de 100 prestataires de soins de santé, révèle que l'industrie des thérapies avancées devrait compter plus de 200 thérapies approuvées et traiter plus de 100 000 patients américains d'ici 2030.
Les principales conclusions mettent en lumière des défis importants dans l'adoption des CGT, avec 56 % des répondants citant des contraintes financières et 54 % pointant un remboursement insuffisant comme obstacles majeurs. Le rapport souligne la nécessité d'une meilleure collaboration entre les acteurs de l'industrie, avec 69 % des répondants soutenant des initiatives stratégiques entre payeurs et fabricants. De plus, 64 % ont identifié un soutien social insuffisant comme la principale raison pour laquelle les patients ne reçoivent pas les traitements CGT nécessaires.
Cardinal Health (NYSE: CAH) hat seinen Bericht zu fortschrittlichen Therapien 2025 veröffentlicht, der umfassende Einblicke in die Zell- und Gentherapiebranche (CGT) bietet. Der Bericht, basierend auf einer Umfrage unter über 100 Gesundheitsdienstleistern, zeigt auf, dass die Branche der fortschrittlichen Therapien bis 2030 über 200 zugelassene Therapien haben und mehr als 100.000 Patienten in den USA behandeln wird.
Wichtige Erkenntnisse heben erhebliche Herausforderungen bei der Einführung von CGT hervor, wobei 56 % der Befragten finanzielle Einschränkungen und 54 % unzureichende Erstattungen als Hauptbarrieren nennen. Der Bericht betont die Notwendigkeit einer verbesserten Zusammenarbeit aller Branchenakteure, wobei 69 % der Befragten strategische Initiativen zwischen Kostenträgern und Herstellern unterstützen. Zudem identifizierten 64 % unzureichende soziale Unterstützung als Hauptgrund dafür, dass Patienten die benötigten CGT-Behandlungen nicht erhalten.
- Projected growth to over 200 approved therapies and 100,000 U.S. patients treated by 2030
- Strong industry recognition of the need for strategic initiatives between payers and manufacturers (69% support)
- Comprehensive market analysis based on extensive healthcare provider survey
- High acquisition costs and financial constraints reported by 56% of respondents
- Lack of adequate reimbursement cited by 54% of respondents
- Significant patient access barriers due to insufficient social support (64%)
- Complex logistics and limited treatment facilities beyond academic centers
Analysis charts the emergence and future of advanced therapies
This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry.
"Cell and gene therapies are poised to revolutionize healthcare treatment for a wide range of diseases," said Craig Cowman, EVP, Biopharma Solutions and Strategic Sourcing at Cardinal Health. "They hold the potential to fundamentally improve the lives of patients with cancer, heart disease, diabetes, and hereditary conditions. Our report provides a comprehensive analysis of the industry's current state and the exciting future that lies ahead."
The report underscores the transformative potential of CGTs, particularly for patients with complex and rare conditions, and documents one patient's experiences with CAR T-cell therapy, including the challenges he encountered along the way.
The advanced therapy industry is poised for rapid growth, with over 200 therapies projected to be approved and more than 100,000
Key Report Findings:
- Challenges to CGT access and adoption persist: Despite the promise of CGTs, there are significant obstacles, including referral processes, high costs, complex logistics and reimbursement uncertainties.
56% of survey respondents stated that financial constraints, such as high acquisition costs, are a barrier.54% said that lack of or inadequate reimbursement is a challenge.
- Collaboration is key to overcoming challenges to access: There is a critical need for improved collaboration across all industry stakeholders, including manufacturers, payers, providers and patients.
69% of survey respondents said that strategic initiatives between payers and manufacturers, such as innovative payment models, are needed for increased access.53% stated that extending facilities beyond academic/medical center hubs is important to improving access to CGTs.
- Many patients still do not receive the CGT treatments they need:
64% of survey respondents cited insufficient social support (e.g., lack of care partner availability, etc.) as the most common reason.57% cited prior authorization denial as another significant reason.
"In many ways, we're still in the very early stages of the incredibly promising CGT industry," said Fran Gregory, Vice President of Emerging Therapies at Cardinal Health. "However, it is also time to take stock of where we stand currently and discuss ideas to help us navigate the significant changes that the growth of these therapies is bringing. Our new report shows how we can move the industry forward."
The report can be accessed here.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.
Contacts
Media: Kelli Nowinsky, kelli.nowinsky@cardinalhealth.com and 614-205-3073
Investors: Matt Sims, matt.sims@cardinalhealth.com and 614.553.3661
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-releases-new-report-on-the-cell-and-gene-therapy-industry-302447744.html
SOURCE Cardinal Health
FAQ
What are the key findings of Cardinal Health's 2025 Advanced Therapies Report on cell and gene therapy?
How many patients are expected to receive cell and gene therapy treatment by 2030 according to CAH's report?
What are the main barriers to cell and gene therapy adoption according to Cardinal Health's 2025 report?
What solutions does Cardinal Health's report suggest for improving CGT access?
